santhera pharmaceuticals

Santhera Completes Enrollment of Phase 3 SIDEROS Study with Puldysa® (Idebenone) in Duchenne

Santhera announced today that their SIDEROS study is fully enrolled, with 254 participants ages 10-34 years old. PPMD is excited to learn that this trial is enrolled, allowing the study to continue and enabling Santhera…

Learn More

Santhera Shares Community Update on SIDEROS Trial & COVID-19

Santhera Pharmaceuticals has shared an update with the community regarding the SIDEROS clinical trial and their activities during the COVID-19 epidemic. Read the update from Santhera Dear Duchenne community, Much has changed in the world…

Learn More

WATCH: Teen & Young Adult Trial Participation in Duchenne – Industry & Community Perspectives – Webinar Recording

On Wednesday, March 4, 2020, Santhera Pharmaceuticals joined PPMD for a webinar to discuss teen and young adult clinical trial participation. We heard from Santhera about lessons learned by conducting one of the largest trials…

Learn More

January 23, 2020

End Duchenne Tour Connect Group Session: Houston, TX

PPMD’s End Duchenne Tour made a stop in Houston, TX on Saturday, January 18. We were joined by over 40 people, including PPMD’s Connect Coordinators for South Texas, several PPMD families, and some of the…

Learn More

January 21, 2020

Santhera Shares Winter 2020 Community Update

Santhera Pharmaceuticals shared a letter with the community, emphasizing that their main focus in the U.S. right now is to bring the SIDEROS clinical trial to full enrollment. Learn more about this clinical trial, including…

Learn More

November 19, 2019

Santhera shares SIDEROS clinical trial and BreatheDMD program update

Santhera Therapeutics shared a community letter today announcing that the company has decided to suspend enrolling new participants in the BreatheDMD expanded access program (EAP) until their SIDEROS clinical trial is fully enrolled. The SIDEROS…

Learn More

November 4, 2019

End Duchenne Tour Recap: Memphis, TN

PPMD’s End Duchenne Tour made a stop in Memphis, TN on Saturday, October 26. We were joined by over 60 people, including families, an amazing group of volunteers in our kids room, six members of…

Learn More

October 9, 2019

2019 World Muscle Society Update – Day 4

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

October 7, 2019

Santhera Announces Presentation by ReveraGen of Positive 18-Month Data with Vamorolone in Duchenne

Santhera Pharmaceuticals has announced the presentation of data showing continued improvement of muscle function and improved tolerability compared with corticosteroids of 18-month vamorolone treatment in Duchenne. PPMD was an earlier funder of this important research…

Learn More

October 7, 2019

2019 World Muscle Society Update – Days 2 & 3

This week, PPMD’s Abby Bronson, SVP of Research Strategy and Eric Camino, PhD, Director of Research and Clinical Innovation are attending the annual World Muscle Society (WMS) meeting, this year in Copenhagen, Denmark. Below, Abby…

Learn More

Join Our Mailing List